Engineered immune cells take on stubborn arthritis in early trial
NCT ID NCT07100873
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment called ADI-001 for adults with rheumatoid arthritis that hasn't improved with standard therapies. ADI-001 uses specially engineered immune cells from a donor to target and destroy faulty immune cells that drive inflammation. The main goal is to check safety and find the right dose, with 25 participants receiving the therapy and being monitored for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Adicet Clinical Trials
RECRUITINGShanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple blood test flag heart risk in rheumatoid arthritis?
- Learning to Self-Care: a new approach to ease RA stiffness?
- Can a specialized hand exercise protocol restore grip and ease pain in rheumatoid arthritis?
- Can less be more? trial tests cutting RA medication doses
- Can a new pill tame rheumatoid arthritis when standard drugs fail?
- Can two common drugs tame rheumatoid arthritis?